Nanotoxicity of poly(n-butylcyano-acrylate) nanoparticles at the blood-brain barrier, in human whole blood and in vivo

Journal of Controlled Release

Volumn 197, Issue , 2015, Pages 165-179

  Kolter, Marise ^a   Ott, Melanie ^a   Hauer, Christian ^a   Reimold, Isolde ^a   Fricker, Gert ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Blood brain barrier; Cytokine; Human blood; Nanoparticle; PBCA; Toxicity

Indexed keywords

CELL DEATH; DISEASE CONTROL; DRUG DELIVERY; EMULSIFICATION; EMULSIONS; METABOLISM; NANOPARTICLES; RATS; TOXICITY;

BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEMS; CONCENTRATION-DEPENDENT; CYTOKINES; HUMAN BLOODS; INFLAMMATORY CYTOKINES; NANOPARTICLE EXPOSURES; PBCA;

BLOOD;

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; NANOPARTICLE; POLY(N BUTYLCYANOACRYLATE) NANOPARTICLE; POLYSORBATE 80; RANTES; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CYTOKINE; ENBUCRILATE; LACTATE DEHYDROGENASE; OXAZINE DERIVATIVE; POLYSORBATE; RESAZURIN; XANTHENE DERIVATIVE;

ADSORPTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CAPILLARY ENDOTHELIAL CELL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; DRUG DELIVERY SYSTEM; EX VIVO STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; NANOEMULSION; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; RAT; SURFACE CHARGE; ZETA POTENTIAL; ANIMAL; BLOOD; BRAIN; CELL CULTURE; CELL SURVIVAL; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; ENDOTHELIUM CELL; METABOLISM; PIG; WISTAR RAT;

ADSORPTION; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CELL SURVIVAL; CELLS, CULTURED; CYTOKINES; ENBUCRILATE; ENDOTHELIAL CELLS; HUMANS; L-LACTATE DEHYDROGENASE; MALE; NANOPARTICLES; OXAZINES; POLYSORBATES; RATS, WISTAR; SWINE; XANTHENES;

EID: 84912072498     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.11.005     Document Type: Article

References (53)

1. J. Scherrmann, Expression and function of multidrug resistance transporters at the blood-brain barriers, Expert Opin. Drug Metab. Toxicol. 1 (2) (2005) 233-246.
2. W.M. Pardridge, The blood-brain barrier: bottleneck in brain drug development, NeuroRx 2 (1) (2005) 3-14.
3. M. Bellavance, M. Blanchette, D. Fortin, Recent advances in blood-brain barrier disruption as a CNS delivery strategy, AAPS J. 10 (1) (2008) 166-177.
4. A. Burgess, K. Hynynen, Noninvasive and targeted drug delivery to the brain using focused ultrasound, ACS Chem. Neurosci. 4 (4) (2013) 519-526.
5. L.H. Treat, N. McDannold, N. Vykhodtseva, Y. Zhang, K. Tam, K. Hynynen, Targeted delivery of doxorubicin to the rat brain at therapeutic levels using MRI-guided focused ultrasound, Int. J. Cancer 121 (4) (2007) 901-907.
6. W.H. Oldendorf, Lipid solubility and drug penetration of the blood brain barrier, Proc. Soc. Exp. Biol. Med. 147 (3) (1974) 813-815.
7. W.M. Pardridge, Vector-mediated drug delivery to the brain, Adv. Drug Deliv. Rev. 36 (2-3) (1999) 299-321.
8. F. Lai, A.M. Fadda, C. Sinico, Liposomes for brain delivery, Expert Opin. Drug Deliv. 10 (7) (2013) 1003-1022.
9. A. Schnyder, J. Huwyler, Drug transport to brainwith targeted liposomes, NeuroRx 2 (1) (2005) 99-107.
10. S. Wohlfart, S. Gelperina, J. Kreuter, Transport of drugs across the blood-brain barrier by nanoparticles, J. Control. Release 161 (2) (2012) 264-273.
11. I. Reimold, D. Domke, J. Bender, C.A. Seyfried, H. Radunz, G. Fricker, Delivery of nanoparticles to the brain detected by fluorescence microscopy, Eur. J. Pharm. Biopharm. 70 (2) (2008) 627-632.
12. J. Kreuter, R.N. Alyautdin, D.A. Kharkevich, A.A. Ivanov, Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles), Brain Res. 674 (1) (1995) 171-174.
13. K.B. Kurakhmaeva, I.A. Djindjikhashvili, V.E. Petrov, V.U. Balabanyan, T.A. Voronina, S.S. Trofimov, et al., Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles, J. Drug Target. 17 (8) (2009) 564-574.
14. P. Ramge, R.E. Unger, J.B. Oltrogge, D. Zenker, D. Begley, J. Kreuter, et al., Polysorbate-80 coating enhances uptake of polybutylcyanoacrylate (PBCA)-nanoparticles by human and bovine primary brain capillary endothelial cells, Eur. J. Neurosci. 12 (6) (2000) 1931-1940.
15. J. Kreuter, Drug delivery to the central nervous system by polymeric nanoparticles: What do we know? Adv. Drug Deliv. Rev. 71C (2014) 2-14.
16. A. Nel, T. Xia, L. Mädler, N. Li, Toxic potential of materials at the nanolevel, Science 311 (5761) (2006) 622-627.
17. G. Oberdorster, A. Maynard, K. Donaldson, V. Castranova, J. Fitzpatrick, K. Ausman, et al., Principles for characterizing the potential human health effects from exposure to nanomaterials: elements of a screening strategy, Part. Fibre Toxicol. 2 (2005) 8.
18. D.C. Morrison, D.M. Jacobs, Binding of polymyxin B to the lipid A portion of bacterial lipopolysaccharides, Immunochemistry 13 (10) (1976) 813-818.
19. N. Savjani, E. Babcock, H.K. Khor, A. Raghani, Use of ferric thiocyanate derivatization for quantification of polysorbate 80 in high concentration protein formulations, Talanta 130 (2014) 542-546.
20. U.S. Department of Health and Human Services, Food and Drug Administration, Guidance for Industry Pyrogen and Endotoxins Testing: Questions and Answers2012.
21. USP 36-NF 31, United States Pharmacopeia: National Formulary, United States Pharmacopeial Convention, Rockville, Md, 2013.
22. P.D. Bowman, S.R. Ennis, K.E. Rarey, A.L. Betz, G.W. Goldstein, Brain microvessel endothelial cells in tissue culture: a model for study of blood-brain barrier permeability, Ann. Neurol. 14 (4) (1983) 396-402.
23. S. Kroll, J. El-Gindi, G. Thanabalasundaram, P. Panpumthong, S. Schrot, C. Hartmann, et al., Control of the blood-brain barrier by glucocorticoids and the cells of the neurovascular unit, Ann. N. Y. Acad. Sci. 1165 (2009) 228-239.
24. K. Benson, S. Cramer, H. Galla, Impedance-based cell monitoring: barrier properties and beyond, Fluids Barriers CNS 10 (1) (2013) 5.
25. R. Rempe, S. Cramer, S. Huwel, H. Galla, Transport of poly(n-butylcyano-acrylate) nanoparticles across the blood-brain barrier in vitro and their influence on barrier integrity, Biochem. Biophys. Res. Commun. 406 (1) (2011) 64-69.
26. K. Watanabe, S. Kinoshita, H. Nakagawa, Purification and characterization of cytokine-induced neutrophil chemoattractant produced by epithelioid cell line of normal rat kidney (NRK-52E cell), Biochem. Biophys. Res. Commun. 161 (3) (1989) 1093-1099.
27. F. Shibata, K. Konishi, H. Nakagawa, Identification of a common receptor for three types of rat cytokine-induced neutrophil chemoattractants (CINCs), Cytokine 12 (9) (2000) 1368-1373.
28. M. Iida, K. Watanabe, M. Tsurufuji, K. Takaishi, Y. Iizuka, S. Tsurufuji, Level of neutrophil chemotactic factor CINC/gro, a member of the interleukin-8 family, associated with lipopolysaccharide-induced in flammation in rats, Infect. Immun. 60 (4) (1992) 1268-1272.
29. A. Ewringmann, B. Glöckner, Leitsymptome bei Hamster, Ratte, Maus und Rennmaus: Diagnostischer Leitfaden und Therapie, 1st ed. Enke, Stuttgart, 2008.
30. J. Hau, S.J. Schapiro, Handbook of Laboratory Animal Science, 3rd ed. CRC; Taylor & Francis, Boca Raton, Fla., London, 2010.
31. K. Landfester, Miniemulsions for Nanoparticle Synthesis, in: M. Antonietti (Ed.), Colloid Chemistry II, Springer Berlin Heidelberg, Berlin, Heidelberg, 2003, pp. 75-123 (Topics in Current Chemistry).
32. W. Sun, C. Xie, H. Wang, Y. Hu, Specific role of polysorbate 80 coating on the targeting of nanoparticles to the brain, Biomaterials 25 (15) (2004) 3065-3071.
33. M. Holzer, V. Vogel, W. Mantele, D. Schwartz, W. Haase, K. Langer, Physico-chemical characterisation of PLGA nanoparticles after freeze-drying and storage, Eur. J. Pharm. Biopharm. 72 (2) (2009) 428-437.
34. R. Mulik, K. Mahadik, A. Paradkar, Development of curcuminoids loaded poly(butyl) cyanoacrylate nanoparticles: physicochemical characterization and stability study, Eur. J. Pharm. Sci. 37 (3-4) (2009) 395-404.
35. O. Maksimenko, E. Pavlov, E. Toushov, A. Molin, Y. Stukalov, T. Prudskova, et al., Radiation sterilisation of doxorubicin bound to poly(butyl cyanoacrylate) nanoparticles, Int. J. Pharm. 356 (1-2) (2008) 325-332.
36. A. Saez, M. Guzman, J. Molpeceres, M.R. Aberturas, Freeze-drying of polycaprolactone and poly(D, L-lactic-glycolic) nanoparticles induce minor particle size changes affecting the oral pharmacokinetics of loaded drugs, Eur. J. Pharm. Biopharm. 50 (3) (2000) 379-387.
37. P. Sommerfeld, B.A. Sabel, U. Schroeder, Long-term stability of PBCA nanoparticle suspensions, J. Microencapsul. 17 (1) (2000) 69-79.
38. N. Lewinski, V. Colvin, R. Drezek, Cytotoxicity of nanoparticles, Small 4 (1) (2008) 26-49.
39. L. Grislain, P. Couvreur, V. Lenaerts, M. Roland, D. Deprez-Decampeneere, P. Speiser, Pharmacokinetics and distribution of a biodegradable drug-carrier, Int. J. Pharm. 15 (3) (1983) 335-345.
40. H.E. de Vries, M.C. Blom-Roosemalen, M. van Oosten, A.G. de Boer, T.J. van Berkel, D.D. Breimer, et al., The influence of cytokines on the integrity of the blood-brain barrier in vitro, J. Neuroimmunol. 64 (1) (1996) 37-43.
41. V.J. Quagliarello, B. Wispelwey, W.J. Long Jr., W.M. Scheld, Recombinant human interleukin-1 induces meningitis and blood -brain barrier injury in the rat. Characterization and comparison with tumor necrosis factor, J. Clin. Invest. 87 (4) (1991) 1360-1366.
42. A.T. Argaw, Y. Zhang, B.J. Snyder, M. Zhao, N. Kopp, S.C. Lee, et al., IL-1beta regulates blood-brain barrier permeability via reactivation of the hypoxia-angiogenesis program, J. Immunol. 177 (8) (2006) 5574-5584.
43. F.M. Brett, A.P. Mizisin, H.C. Powell, I.L. Campbell, Evolution of neuropathologic abnormalities associated with blood-brain barrier breakdown in transgenic mice expressing interleukin-6 in astrocytes, J. Neuropathol. Exp. Neurol. 54 (6) (1995) 766-775.
44. M.A. Deli, L. Descamps, M.P. Dehouck, R. Cecchelli, F. Joo, C.S. Abraham, et al., Exposure of tumor necrosis factor-alpha to luminal membrane of bovine brain capillary endothelial cells cocultured with astrocytes induces a delayed increase of permeability and cytoplasmic stress fiber formation of actin, J. Neurosci. Res. 41 (6) (1995) 717-726.
45. M. Fiala, D.J. Looney, M. Stins, D.D. Way, L. Zhang, X. Gan, et al., TNF-alpha opens a paracellular route for HIV-1 invasion across the blood-brain barrier, Mol. Med. 3 (8) (1997) 553-564.
46. T. Kossmann, P.F. Stahel, P.M. Lenzlinger, H. Redl, R.W. Dubs, O. Trentz, et al., Interleukin-8 released into the cerebrospinal fluid after brain injury is associated with blood -brain barrier dysfunction and nerve growth factor production, J. Cereb. Blood Flow Metab. 17 (3) (1997) 280-289.
47. I. Iavicoli, E.J. Calabrese, M.A. Nascarella, Exposure to nanoparticles and hormesis, Dose Response 8 (4) (2010) 501-517.
48. M.A. Nascarella, E.J. Calabrese, A method to evaluate hormesis in nanoparticle dose-responses, Dose Response 10 (3) (2012) 344-354.
49. Lilian E. van Vlerken, T.K. Vyas, M.M. Amiji, Poly(ethylene glycol)-modified nanocarriers for tumor-targeted and intracellular delivery, Pharm. Res. 24 (8) (2007) 1405-1414.
50. D.E. Owens, N.A. Peppas, Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles, Int. J. Pharm. 307 (1) (2006) 93-102.
51. M. Kataranovski, Z. Magic, N. Pejnovic, Early inflammatory cytokine and acute phase protein response under the stress of thermal injury in rats, Physiol. Res. 48 (6) (1999) 473-482.
52. G.D. Martich, R.L. Danner, M. Ceska, A.F. Suffredini, Detection of interleukin 8 and tumor necrosis factor in normal humans after intravenous endotoxin: the effect of antiinflammatory agents, J. Exp. Med. 173 (4) (1991) 1021-1024.
53. L. Thomas, Labor und Diagnose: Indikation und Bewertung von Laborbefunden für die medizinische Diagnostik, 8th ed. TH-Books Verlagsgesellschaft, Frankfurt am Main, 2012.